4D Molecular Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
4D Molecular Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$51.1M, a 266% decline year-over-year.
  • 4D Molecular Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$168M, a 60.5% decline year-over-year.
  • 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$113M, a 2.58% decline from 2022.
  • 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$110M, a 54.3% decline from 2021.
  • 4D Molecular Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$71.3M, a 25.9% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$113M -$2.84M -2.58% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-29
2022 -$110M -$38.7M -54.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 -$71.3M -$14.7M -25.9% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$56.7M -$5.9M -11.6% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
2019 -$50.8M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.